RxDoctor Payments Data

Asha Shrestha, MD

Rheumatology · Orono, MENPI 1336378405

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 79.5% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $260, more than ten times the $17 reported in 2021.

$622in general payments, 2019–2025

Across 9 payments — averaging $69.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$495
  • Novartis$98
  • Amgen$17
  • Baxter Healthcare$12

What the payments were for

  • Food & beverage$60096%
  • Education$102%
  • Other$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie5$495
Novartis2$98
Amgen1$17
Baxter Healthcare1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$622 in reported general payments places this provider in the 75th percentile of 28 rheumatology providers in Maine.

See all rheumatology providers in Maine

Medicare billing

Part B allowed, 2024
$1,173,260
Medicare patients
603
Services billed
65,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept126$1,027,342
Humira(Cf) PenAdalimumab67$694,099
OtezlaApremilast75$381,484
Xeljanz XrTofacitinib Citrate41$291,970
EnbrelEtanercept29$287,288
Cosentyx Sensoready (2 Pens)Secukinumab18$154,428
Actemra ActpenTocilizumab27$140,506
RinvoqUpadacitinib11$73,239
OrenciaAbatacept12$63,894
Hydroxychloroquine Sulfate686$32,259
MethotrexateMethotrexate Sodium483$16,892
Leflunomide120$11,609
Cevimeline Hcl37$5,387
Colchicine53$5,152
Prednisone458$4,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$17$668,773104 claims
AbbVieRinvoq$495$73,23911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 28 rheumatology providers in Maine.

Other rheumatology in Orono

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →